biologic

Vyvgart Hytrulo

efgartigimod alfa and hyaluronidase-qvfc

Loss of exclusivityJune 2035projected — 12-year biologic exclusivity estimate
CompanyArgenx BV

Drug detail

Brand nameVyvgart Hytrulo
Active ingredientefgartigimod alfa and hyaluronidase-qvfc
Strength1,008MG/5.6ML; 11,200UNITS/5.6ML (180MG/2,000UNITS/ML)
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalJune 2023
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Not found